Attention www.globalkeysolutions.net is now www.keypedia.com, read the full press release here.
KeyPedia LogoKeyPedia Icon
  1. Home
  2. /
  3. Records
  4. /
  5. Warning Letter
  6. /
  7. Novel Laboratories, Inc. d.b.a Lupin Somerset
WARNING LETTER
•Novel Laboratories, Inc. d.b.a Lupin Somerset•November 5, 2020

Novel Laboratories, Inc. d.b.a Lupin Somerset – FDA Warning Letter, Nov 5, 2020

Record Details

The FDA issued a Warning Letter to Novel Laboratories, Inc. d.b.a. Lupin, following an inspection from September 10 to November 5, 2020, at their Somerset, New Jersey facility. The letter identifies significant violations of current good manufacturing practice (CGMP) regulations (21 CFR parts 210 and 211), rendering their drug products adulterated. Key deficiencies include inadequate written procedures for equipment cleaning and maintenance (21 CFR 211.67(b)), leading to observed drug residue and cross-contamination risks on non-dedicated equipment. The firm also failed to establish adequate written procedures for production and process control (21 CFR 211.100(a)), specifically regarding the inadequate validation of temazepam capsule manufacturing processes after equipment and process changes, resulting in out-of-specification (OOS) content uniformity results. Furthermore, the Quality Control Unit (QU) failed to establish and follow adequate written responsibilities and procedures (21 CFR 211.22(d)), demonstrating insufficient oversight in cleaning validation protocol review and annual product review completion. The FDA noted repeat violations at multiple Lupin sites, indicating inadequate corporate oversight. The company must provide a written response within 15 working days, detailing corrective actions, including testing of reserve samples for cross-contamination, a comprehensive retrospective assessment of cleaning effectiveness, a CAPA plan, improvements to cleaning validation and process validation programs, and a remediation plan for the QU. Failure to address these violations promptly may result in regulatory actions, including seizure, injunction, and withholding of new application approvals or export certificates.

Company
Novel Laboratories, Inc. d.b.a Lupin Somerset
Inspection date
November 5, 2020
Product type
Drugs
Office
Office of Pharmaceutical Quality Operations Division I
People
  • Diana Amador-Toro (District Director)
  • Ronald W. Overhiser
View Company Profile

ID · 8db1077e-e83a-4e3a-8141-a77b0e62df2c

Violation Codes8
21 CFR 21021 CFR 211FD&C Act 501(a)(2)(B)21 CFR 211.67(b)21 CFR 211.100(a)21 CFR 211.22(d)21 CFR 211.67(a)21 U.S.C. 351(a)(2)(B)

Full citation text and observation details available on the Dashboard.

Other documents for Novel Laboratories, Inc. d.b.a Lupin Somerset
  • 483 - 2026-04-17April 17, 2026
  • 483 - 2025-10-10October 10, 2025
  • 483 - 2023-01-13January 13, 2023
  • 483 - 2022-03-30March 30, 2022
  • 483 - 2020-11-05November 5, 2020

Your cart

Your cart is empty.

Browse public document pages and click Buy this document. We'll ask for your email at checkout, no account needed up front.

Browse documents

Discuss this record with AI

KeyPedia

ChatGPT

Claude

Perplexity

Grok

Copilot

Document or profile

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore Novel Laboratories, Inc. d.b.a Lupin Somerset
KeyPedia
Regulatory Data Transformed
Stay in the loop

KRA score changes, company updates and news. About monthly, unsubscribe anytime.

Contact
New York Office:
370 Jay Street 7th Floor
Brooklyn, NY 11201
Scranton Office:
Scranton Enterprise Center, Suite 217
201 Lackawanna Avenue
Scranton, PA, 18503
🇺🇸+1 917-789-5099
🇪🇺+48 532-447-507
info@keypedia.com
Quick Links
HomePlatform OverviewMedia
KeyPedia™ Lite
Browse HubDatabase DirectoryRecordsCompaniesOfficesPeopleCareersAbout UsFounding TeamMeet Our ExpertsPartners
Legal & Ethics
Privacy PolicyTerms of ServiceOur Values & MissionCode of Ethics & AI Policy
©2026 KeyPedia™ | Global Key Solutions Corp. All rights reserved.